DAPA-HF, REWIND, other cardiometabolic science highlighted at CMHC



CHICAGO — Healio presents live updates from the late-breaking trials session at the Cardiometabolic Health Congress.
Presenters highlighted notable recent research involving drugs to address diabetes and cardiometabolic health, including DECLARE-TIMI 58, REWIND, GLP-1 receptor agonist and SGLT2 inhibitor meta-analyses and DAPA-HF.
DECLARE-TIMI 58 trial
Beyond improved cardiovascular outcomes, the SGLT2 inhibitor dapagliflozin (Farxiga, AstraZeneca) may also offer adults with type 2 diabetes the potential to prevent and treat kidney disease, according to findings published in The Lancet



Source link

Leave a Reply!

So glad to see you sticking around!

Want to be the first one to receive the new stuff?

Enter your email address below and we'll send you the goodies straight to your inbox.

Thank You For Subscribing!

This means the world to me!

Spamming is not included! Pinky promise.